TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
Rupert Bartsch • 5 May 2022
ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer
Rupert Bartsch • 7 Dec 2022
Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter